COMPASS Pathways logo

COMPASS Pathways

CMPS | NASDAQ
Chart Builder DCF Calculator
$8.27
-$0.74 (-8.21%)
At close: Nov 16, 2026, 4:00 PM ET
$8.33
+$0.06 (+0.69%)
After-hours: Nov 16, 2026, 7:53 PM ET
-8.21%

Rating

Updated: Nov 16, 2026
24.1
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #951/1021 (Top 93%)

Key Statistics

Market Data

Market Cap $1.17B
1D Range
8.18 8.92
52W Range
4.94 15.19

Valuation (TTM)

PE -1.86
PB 8.25
EV/EBITDA -2.96

Valuation (NTM)

Forward PE N/A
Forward PEG 0.07
Price Target $20.00
Loading financial charts...

Profile

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on develo...

Sector Healthcare
Industry Biotechnology
Employees 156
IPO Date Sep 18, 2020
Fiscal Year January - December

Latest News

Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch

4 days ago · marketbeat.com

Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th

5 days ago · businesswire.com

Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression

8 days ago · businesswire.com

Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th

13 days ago · businesswire.com

Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
Compass Pathways: 3 Key Takeaways for Long-Term Investors

13 days ago · fool.com

Compass Pathways: 3 Key Takeaways for Long-Term Investors
COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript

14 days ago · seekingalpha.com

COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers

15 days ago · businesswire.com

New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
1 Reason Compass Pathways Is Worth a Second Look This Month

15 days ago · fool.com

1 Reason Compass Pathways Is Worth a Second Look This Month
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress

20 days ago · businesswire.com

Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

20 days ago · seekingalpha.com

Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$20.50
Upside
+147.88%
Buy (10)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.